Welcome to inquiry!
Email: tony@kafenbio.com
WhatsApp: +8618002259573
Skype: tony_14616
www.pharmhormone.com
High Purity Estrogen Raw Female Steroid Powders Ethynyl Estradiol 57-63-6
Ethynyl Estradiol Basic Info.:
Ethynyl estradiol Basic information
Product Name: Ethynyl estradiol
CAS: 57-63-6
MF: C20H24O2
MW: 296.4
EINECS: 200-342-2
Chemical Properties: Off-White to Light-Yellow Crystalline Powder
Usage: A metabolite of 17A-Ethynylestradiol
Usage: A synthetic steroid with high oral estrogenic potency
Usage estrogen, plus progestogen as oral contraceptive
Standard: USP28
Ethynyl Estradiol Description:
Ethinylestradiol is a man-made form of the naturally occurring female hormone called oestrogen.
It is prescribed to treat period (menstrual) problems, and also to help ease menopausal symptoms. It is usually prescribed alongside another female hormone called a progestogen.
Ethinyl estradiol also sometimes written as ethinylestradiol, ethynyl estradiol, or ethinyl? Stradiol, is a derivative of 17β -estradiol (E2), the major endogenous estrogen in humans. EE is an orally bioactive estrogen used in many formulations of combined oral contraceptive pills. It is one of the most commonly used medications for this purpose.
Estinyl was a preparation of EE alone that was used for the management of menopausal symptoms and female hypogonadism.
EE is released into the environment as a xenoestrogen from the urine and feces of people who take it as a medication.
Ethynyl Estradiol Application:
When estrogen is prescribed for a woman with a uterus, progestin should also be initiated to reduce the risk of endometrial cancer. A woman without a uterus does not need progestin. Use of estrogen, alone or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Patients should be reevaluated periodically as clinically appropriate (e.g., 3-month to 6-month intervals) to determine if treatment is still necessary. For women who have a uterus, adequate diagnostic measures, such as endometrial sampling, when indicated, should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Short-term cyclic use for treatment of moderate to severe vasomotor symptoms, vulval and vaginal atrophy associated with the menopause, the lowest dose and regimen that will control symptoms should be chosen and medication should be discontinued as promptly as possible.
Attempts to discontinue or taper medication should be made at 3- to 6-month intervals. The usual dosage range is 1 to 5 mg injected every 3 to 4 weeks.
For treatment of female hypoestrogenism due to hypogonadism 1.5 to 2 mg injected at monthly intervals.
Suppliers